(-0.34%) 5 018.39 points
(0.23%) 37 903 points
(-0.33%) 15 605 points
(0.28%) $79.22
(0.98%) $1.951
(0.98%) $2 333.70
(1.04%) $27.03
(1.37%) $968.00
(0.04%) $0.933
(0.05%) $11.03
(-0.02%) $0.798
(0.06%) $93.51
Live Chart Being Loaded With Signals
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally...
Stats | |
---|---|
本日の出来高 | 8 679.00 |
平均出来高 | 63 470.00 |
時価総額 | 178.26M |
EPS | €0 ( 2024-03-20 ) |
次の収益日 | ( €0 ) 2024-05-09 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -24.50 |
ATR14 | €0.0120 (0.54%) |
Innate Pharma SA 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Innate Pharma SA 財務諸表
Annual | 2023 |
収益: | €51.90M |
総利益: | €-4.12M (-7.94 %) |
EPS: | €-0.0941 |
FY | 2023 |
収益: | €51.90M |
総利益: | €-4.12M (-7.94 %) |
EPS: | €-0.0941 |
FY | 2022 |
収益: | €49.64M |
総利益: | €-2.02M (-4.08 %) |
EPS: | €-1.240 |
FY | 2021 |
収益: | €12.11M |
総利益: | €0.00 (0.00 %) |
EPS: | €-0.669 |
Financial Reports:
No articles found.
Innate Pharma SA
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。